Genotyping Assay Market

The global genotyping assay market is expected to grow from $19.4 billion in 2024 to $37.1 billion by 2029, at a CAGR of 13.8%. This growth is driven by advancements in DNA sequencing technology, rising prevalence of genetic disorders, and increased application in personalized medicine and drug development. Key market drivers include the growing use of genotyping in drug discovery and development, while high instrument costs act as a restraint. Opportunities lie in expanding applications in animal genetics and agricultural biotechnology. North America dominates the market, and major players include Thermo Fisher Scientific, Illumina, and QIAGEN. The market is segmented by product & services, technology, applications, end-users, and regions. Reagents & kits and PCR technologies lead in market share, with pharmacogenomics being the largest application segment.

Genotyping Assay Market Trends

To know about the assumptions considered for the study, Request for Free Sample Report

Genotyping Assay Market Dynamics

Driver: Growing importance and use of genotyping in drug discovery and development

With the increased availability of investments and government funding for conducting genomics-based research, several CROs and academic researchers have started gene-based research studies to develop innovative disease management strategies with the help of genotyping. The increasing demand for pharmacogenomics is highlighting the potential for growth in genotyping tests. The drug discovery and development market has increasingly adopted these tests for assessing drug efficacy and safety and finding new biomarker assays for drug profile assessment, toxicity prediction, risk assessment, dosing determination, treatment decision-making, and drug response evaluation. Thus, the growing importance and use of genotyping in the drug discovery and development process is expected to drive market growth.

Restraint: High manufacturing, installation, and maintenance costs of genotyping instruments

Genotyping instruments are equipped with advanced features and functionalities, making them highly-priced. Pharmaceutical companies and research laboratories require a number of such systems, creating the need for significant investments in procuring multiple high-cost genotyping instruments. For instance, the Genome Institute at Washington University is reported to have 30 sequencing instruments (Illumina HiSeq 2000s) costing an estimated USD 750,000 each. Academic research laboratories also find it difficult to afford such systems due to budget constraints. Maintenance costs and several other indirect expenses, such as sample and labor costs, also result in an overall increase in the total cost of ownership of these instruments. As a result, the installation/expansion of advanced research facilities such as NGS technology is hampered in academic and research institutes in emerging countries across Asia, the Middle East, and Africa.

Opportunity: Increasing application areas in genomics and genotyping analysis for animal genetics and agricultural biotechnology

Although the identification of human genetic disorders and drug discovery are the major application areas of genomics, its application in agriculture, veterinary sciences, and forensics, among other fields, has increased in recent years to identify quality and produce desirable genetic traits, increase the productivity and quality of food, ensure the safety of food, improve the health of animals, diagnose genetic disorders, search for disease prevention and treatment options, and improve sustainability. The application of genomics in forensic studies has improved drastically with the advent of NGS. Earlier, DNA analysis was used for fingerprint profiling, which is now being replaced by genomic recreation of the complete genome

Challenge: Lack of adequate data management in genomics research

Large amounts of data are produced by genotyping research, both quantitative and qualitative. Previously, this data was manually saved, which posed a significant problem because gigabytes of data could be generated in a matter of hours. By developing databases to store genotyping data, technological improvements have made data storage more automated. For technologists, comprehending the complete potential of these datasets presents an additional challenge.

Genotyping assay Ecosystem/Market Map

In 2023, Reagents & Kits segment accounted for the highest CAGR of the genotyping assay industry

The genotyping assay market is mainly divided into four segments based on product and service: bioinformatics, instruments, reagents and kits, and GENOTYPING ASSAY services. In 2023, the Genotyping assay's greatest share was held by the reagents & kits category. The significant portion of this market can be ascribed to the availability of a broad variety of reagents, the rising demand for reagents as a result of the global increase in GENOTYPING ASSAY test volumes, and the comparatively lower initial investment needed to implement reagents and kits for GENOTYPING Assay in pharmacies and diagnostic facilities.

In 2023, The polymerase chain reaction (PCR) segment accounted for the market share in the genotyping assay industry, by technology, during the forecast period

Polymerase chain reaction (PCR), microarrays, capillary electrophoresis, sequencing, matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF), and other technologies (in situ hybridization and allele-specific oligonucleotides) are the main technological segments of the genotyping assay market. In 2023, the PCR segment held the greatest proportion of the market for GENOTYPING ASSAY technology. The main factors propelling the growth of the PCR market are the introduction of new technologies like reverse transcriptase PCR, nested PCR, hot-start PCR, allele-specific PCR, and multiplex PCR; technological developments in PCR instruments and reagents; and the growing use of PCR technologies in the domains of genetics, prenatal testing, forensics, and personalized medicine.

In 2023, Pharmacogenomics segment accounted for the highest share of the industry

Pharmacogenomics, diagnostics & personalized medicine, agricultural biotechnology, animal genetics, and other applications make up the majority of the market's application segments. In terms of GENOTYPING ASSAY applications, the pharmacogenomics sector held the biggest share of the genotyping assay market in 2023. The need to lower the overall cost of medication development for pharmaceutical companies and the growing demand for pharmacogenomics to research adverse drug reactions (ADRs) in clinical trials are the primary drivers of growth in this market. The pharmacogenomics genetyping test is predicted to grow due to various factors, including the rising need for personalized medication, the rise in hereditary and life-threatening disorders, and ongoing research on effective and alternative drug delivery techniques.

In 2023, Biopharmaceutical & pharmaceutical companies segment accounted for the highest share of the genotyping assay industry

The genotyping assay market is mainly divided into diagnostic laboratories, academic & research institutes, biopharmaceutical & pharmaceutical firms, and other end users based on end user classification. In 2023, the biopharmaceutical & pharmaceutical companies segment held the greatest share of the end-user market for GENOTYPING ASSAY. The significant market share of this industry may be ascribed to the growing need for pharmacogenomics in the drug research and discovery process, the introduction of new products, and FDA recommendations to incorporate pharmacogenomics studies and GENOTYPING ASSAY in the drug discovery process. Furthermore, growing partnerships and funding for pharmacogenomics research further support the expansion of this market sector for GENOTYPING ASSAY.

North America is the largest regional market for genotyping assay industry

The global genotyping assay market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America held the most market share for genotyping assay worldwide in 2023. The expansion of the North American market may be ascribed to the relationship between rising population and rising levels of research.

To know about the assumptions considered for the study, download the pdf brochure

The major players in this market are Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Danaher Corporation (US), QIAGEN (Netherlands), Eurofins Scientific (Luxembourg). The market leadership of these players stems from their comprehensive product portfolios and expanding global footprint. These dominant market players possess several advantages, including strong marketing and distribution networks, substantial research and development budgets, and well-established brand recognition.

Scope of the Genotyping Assay Industry

This report categorizes the genotyping assay market to forecast revenue and analyze trends in each of the following submarkets:

By Product and Services

• Reagents & Kits
• Genotyping Services
• Instruments
  • Sequencers and Amplifiers
  • Analyzers
• Bioinformatics
  • Software
  • Services

By Technology

• Polymerase Chain Reaction
  • Real-Time Polymerase Chain Reaction
  • Digital Polymerase Chain Reaction
• Microarrays
• Sequencing
  • Next-Generation Sequencing
  • Pyrosequencing
  • Sanger Sequencing
• Capillary Electrophoresis
  • Amplified Fragment Length Polymorphism
  • Restriction Fragment Length Polymorphism
  • Single-Strand Confirmation Polymorphism
• Matrix-assisted Laser Desorption/Ionization-time of Flight
• Other Technologies

By Application

• Pharmacogenomics
• Diagnostics and Personalized Medicine
• Animal Genetics
• Agricultural Biotechnology
• Other Applications

By End User

• Pharmaceutical & Biopharmaceutical Companies
• Diagnostic Laboratories
• Academic & Research Institutes
• Other End Users

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East Africa
• GCC Countries

Recent Developments of the genotyping assay industry:

• In February 2023, Agilent launched an On-deck thermal cycler that provides thermal cycling as part of an automated workflow for NGS, end-point PCR, and cell-based applications..
• In May 2023, Illumina Connected Insights, a new cloud-based software that enables tertiary analysis for clinical next-generation sequencing data. This software will help with genomic profiling (CGP) for advanced tumors, along with whole-genome sequencing for rare diseases and other advanced applications.
• In January 2023, QIAGEN launched the QIAseq Targeted DNA Pro Panels and the QIAseq UPXome RNA Library Kits.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst